MCID: PRS030
MIFTS: 52

Persistent Fetal Circulation Syndrome

Categories: Cardiovascular diseases, Fetal diseases

Aliases & Classifications for Persistent Fetal Circulation Syndrome

MalaCards integrated aliases for Persistent Fetal Circulation Syndrome:

Name: Persistent Fetal Circulation Syndrome 12 29 6 43 15 17 71
Persistent Fetal Circulation 12 32
Fetal Circulation 12 15
Congenital Alveolar Capillary Dysplasia with Misalignment of Pulmonary Veins 12
Persistent Pulmonary Hypertension of the Newborn 12
Persistent Foetal Circulation Syndrome 12
Persistent Foetal Circulation 12

Classifications:



External Ids:

Disease Ontology 12 DOID:13042
ICD9CM 34 747.83
MeSH 43 D010547
NCIt 49 C85006
SNOMED-CT 67 233815004
ICD10 32 P29.3
UMLS 71 C0031190

Summaries for Persistent Fetal Circulation Syndrome

MalaCards based summary : Persistent Fetal Circulation Syndrome, also known as persistent fetal circulation, is related to congestive heart failure and eclampsia. An important gene associated with Persistent Fetal Circulation Syndrome is FOXF1 (Forkhead Box F1), and among its related pathways/superpathways are AMP-activated Protein Kinase (AMPK) Signaling and PI3K-Akt signaling pathway. The drugs Oxycodone and Sodium citrate have been mentioned in the context of this disorder. Affiliated tissues include lung, heart and brain, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 74 Persistent fetal circulation is a condition caused by a failure in the systemic circulation and... more...

Related Diseases for Persistent Fetal Circulation Syndrome

Diseases related to Persistent Fetal Circulation Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 331)
# Related Disease Score Top Affiliating Genes
1 congestive heart failure 30.8 PDE5A NOS3 INS EDN1 ALB
2 eclampsia 30.8 PGF OXT NOS3 EDN1 ALB
3 tricuspid valve insufficiency 30.7 PDE5A EDN1 ALB
4 diaphragmatic hernia, congenital 30.6 PDE5A NOS3 FOXF1 EDN1
5 severe pre-eclampsia 30.6 PGF LEP ALB
6 inherited metabolic disorder 30.5 POMC LEP INS ALB
7 oligohydramnios 30.5 PGF OXT EDN1
8 patent ductus arteriosus 1 30.4 FOXF1 EDN1 ALB
9 vascular disease 30.4 NOS3 LEP INS IGF1 EDN1 ALB
10 muscle hypertrophy 30.4 LEP IGF1 EDN1
11 pulmonary hypertension 30.3 PDE5A NOS3 FOXF1 EDN1 ALB
12 glycogen storage disease 30.3 INS IGF2 IGF1 ALB
13 hypoglycemia 30.2 POMC INS IGF2 IGF1 CRH
14 pain agnosia 30.1 POMC OXT ALB
15 choriocarcinoma 30.1 IGF2 HSD11B2 CSH2 CSH1
16 hyperinsulinism 29.8 LEP INS IGF2 IGF1 EDN1
17 placenta disease 29.7 PGF OXT INS IGF2 CSH2 CSH1
18 diabetes mellitus 29.7 POMC PDE5A NOS3 LEP INS IGF2
19 gestational diabetes 29.6 PGF LEP INS IGF2 IGF1 CSH2
20 pre-eclampsia 29.4 PGF PDE5A OXT NOS3 LEP INS
21 heart disease 29.3 PGF PDE5A NOS3 LEP INS IGF1
22 alveolar capillary dysplasia with misalignment of pulmonary veins 11.6
23 fetal erythroblastosis 11.1
24 testicular trophoblastic tumor 10.7 CSH2 CSH1
25 rete ovarii adenoma 10.7 CSH2 CSH1
26 rete ovarii benign neoplasm 10.6 CSH2 CSH1
27 gestational ovarian choriocarcinoma 10.6 CSH2 CSH1
28 choriocarcinoma of ovary 10.6 CSH2 CSH1
29 choriocarcinoma of the testis 10.6 CSH2 CSH1
30 immunodeficiency 43 10.6 FCGRT ALB
31 non-gestational ovarian choriocarcinoma 10.6 CSH2 CSH1
32 secondary adrenal insufficiency 10.6 INS IGF1
33 genetic obesity 10.6 LEP IGF1
34 chronic pulmonary heart disease 10.6 PDE5A NOS3 EDN1
35 syndromic obesity 10.6 POMC LEP
36 subacute glomerulonephritis 10.5 POMC ALB
37 gestational trophoblastic neoplasm 10.5 PGF CSH2 CSH1
38 supine hypotensive syndrome 10.5 OXT CSH2 CSH1
39 tricuspid valve disease 10.5 PDE5A EDN1 ALB
40 hepatopulmonary syndrome 10.5 NOS3 EDN1 ALB
41 rh isoimmunization 10.5 CSH2 CSH1
42 angina pectoris 10.5 NOS3 INS EDN1
43 diabetic angiopathy 10.5 NOS3 INS EDN1
44 hepatic vascular disease 10.5 NOS3 EDN1 ALB
45 renal hypertension 10.5 NOS3 EDN1 ALB
46 severe nonproliferative diabetic retinopathy 10.5 PGF INS ALB
47 steroid inherited metabolic disorder 10.5 POMC INS HSD11B2
48 graves disease 1 10.5 POMC INS ALB
49 classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency 10.5 POMC LEP
50 hypoglycemic coma 10.5 POMC INS IGF2

Graphical network of the top 20 diseases related to Persistent Fetal Circulation Syndrome:



Diseases related to Persistent Fetal Circulation Syndrome

Symptoms & Phenotypes for Persistent Fetal Circulation Syndrome

MGI Mouse Phenotypes related to Persistent Fetal Circulation Syndrome:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.25 ALB CTBS EDN1 FOXF1 HSD11B2 IGF1
2 homeostasis/metabolism MP:0005376 10.17 ALB CRH CTBS EDN1 FCGRT HSD11B2
3 endocrine/exocrine gland MP:0005379 10.07 ALB CRH EDN1 IGF1 IGF2 INS
4 adipose tissue MP:0005375 10.06 CRH IGF1 INS LEP NOS3 OXT
5 digestive/alimentary MP:0005381 10.06 ALB EDN1 FOXF1 HSD11B2 IGF2 INS
6 immune system MP:0005387 10 ALB CRH CTBS FCGRT IGF1 IGF2
7 liver/biliary system MP:0005370 9.76 ALB CRH CTBS IGF2 INS LEP
8 muscle MP:0005369 9.61 ALB EDN1 FOXF1 HSD11B2 IGF1 IGF2
9 renal/urinary system MP:0005367 9.4 ALB CRH CTBS EDN1 HSD11B2 IGF1

Drugs & Therapeutics for Persistent Fetal Circulation Syndrome

Drugs for Persistent Fetal Circulation Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 85)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
2
Sodium citrate Approved, Investigational Phase 4 68-04-2
3
tannic acid Approved Phase 4 1401-55-4
4
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
5
Adenosine Approved, Investigational Phase 4 58-61-7 60961
6
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
7
Succinylcholine Approved Phase 4 306-40-1 5314
8
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
9
Iloprost Approved, Investigational Phase 4 78919-13-8 6443959
10
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
11
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
12 Narcotics Phase 4
13 Analgesics, Opioid Phase 4
14 Anesthetics Phase 4
15 Pharmaceutical Solutions Phase 4
16 Phosphodiesterase 5 Inhibitors Phase 4
17 Phosphodiesterase Inhibitors Phase 4
18 Citrate Phase 4
19 Sildenafil Citrate Phase 4 171599-83-0
20 Antibodies Phase 4
21 Immunoglobulins Phase 4
22 Rho(D) Immune Globulin Phase 4
23 Immunoglobulins, Intravenous Phase 4
24 gamma-Globulins Phase 4
25 Immunologic Factors Phase 4
26 Neuromuscular Blocking Agents Phase 4
27 Hormones Phase 4
28 Anti-Inflammatory Agents Phase 4
29 Hormone Antagonists Phase 4
30 glucocorticoids Phase 4
31
Ephedrine Approved Phase 2, Phase 3 299-42-3 9294
32
Phenylephrine Approved Phase 2, Phase 3 59-42-7 6041
33
Pseudoephedrine Approved Phase 2, Phase 3 90-82-4 7028
34
Oxymetazoline Approved, Investigational Phase 2, Phase 3 1491-59-4 4636
35
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
36
Enoxaparin Approved Phase 3 9005-49-6 772
37
Dalteparin Approved Phase 3 9005-49-6
38
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
39
Bosentan Approved, Investigational Phase 3 147536-97-8 104865
40 Cardiotonic Agents Phase 2, Phase 3
41 Adrenergic alpha-Agonists Phase 2, Phase 3
42 Central Nervous System Stimulants Phase 2, Phase 3
43 Adrenergic Agents Phase 2, Phase 3
44 Vasoconstrictor Agents Phase 2, Phase 3
45 Nasal Decongestants Phase 2, Phase 3
46 Adrenergic Agonists Phase 2, Phase 3
47 Mydriatics Phase 2, Phase 3
48 Sympathomimetics Phase 2, Phase 3
49 Fibrinolytic Agents Phase 3
50 Anticoagulants Phase 3

Interventional clinical trials:

(show top 50) (show all 75)
# Name Status NCT ID Phase Drugs
1 The Effect of Oxycodone to the Placental Circulation at Early Labour Unknown status NCT02573831 Phase 4 Oxycodone;Placebo
2 Oral Sildenafil in Persistent Pulmonary Hypertension Secondary to Meconium Aspiration Syndrome in Newborns: A Randomized Placebo Controlled Trial Completed NCT01757782 Phase 4 Oral Sildenafil;Placebo (distilled water)
3 Inhaled Nitric Oxide in Neonates With Elevated A-aDO2 Gradients Not Requiring Mechanical Ventilation Completed NCT00732537 Phase 4 inhaled Nitric Oxide;Oxygen (>90% by hood) - standard therapy
4 A Double-blind, Randomized, Parallel Design Study to Compare Surgical Conditions for Fetus Delivery and Suture of the Uterus and Abdominal Wall in Cesarean Section Under General Anesthesia With Deep Neuromuscular Blockade Versus Succinylcholine Completed NCT01941628 Phase 4 Rocuronium;Succinylcholine
5 Phase 4 Study of Use of High-dose Intravenous Immune Globulin for Prevent Hyperbilirubinemia Due Rh Hemolytic Disease in Newborns Infants Completed NCT00288600 Phase 4 Intravenous Immunoglobulin;Normal saline solution
6 Pilot Study: The Effect of Inhaled Iloprost on Oxygenation in Term and Near Term Infants With Pulmonary Hypertension. Testing Two Doses. Terminated NCT00409526 Phase 4 Inhaled Iloprost
7 Randomized Trial on Efficacy and Safety of the Antenatal Rescue Course of Glucocorticoids in Threatened Premature Birth (ACG Trial) Terminated NCT00295464 Phase 4 Betamethasone sodium phos (drug)
8 Effect of Early iNO on Oxidative Stress, Vascular Tone and Inflammation in Term and Late-Preterm Infants With Hypoxic Respiratory Failure Withdrawn NCT01891500 Phase 4 Inhaled nitric oxide;Nitrogen Gas;Crossover iNO
9 Early Combined Use of Inhaled Nitric Oxide and Oral Sildenafil on the Outcome of Pulmonary Hypertension in New Born Infants Unknown status NCT01558466 Phase 3 Sildenafil;diluent
10 The Effect of Vaginal Progestrone on Fetal and Maternal Doppler Indices Completed NCT03292939 Phase 2, Phase 3
11 Low-molecular-weight Heparin in Constituted Vascular Intrauterine Growth Restriction. Randomized Multicenter Trial Completed NCT02672566 Phase 3 Enoxaparin
12 Ephedrine Versus Phenylephrine Infusion for Prevention of Spinal Hypotension During Cesarean Section: Effect on Maternal Cardiodynamics and Fetal Circulation: Randomized Double-blind Study Completed NCT03047109 Phase 2, Phase 3 Phenylephrine;Ephedrine
13 A MULTI-CENTRE, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, TWO-ARMED, PARALLEL GROUP STUDY TO EVALUATE EFFICACY AND SAFETY OF IV SILDENAFIL IN THE TREATMENT OF NEONATES WITH PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN (PPHN) OR HYPOXIC RESPIRATORY FAILURE AND AT RISK FOR PPHN, WITH A LONG TERM FOLLOW-UP INVESTIGATION OF DEVELOPMENTAL PROGRESS 12 AND 24 MONTHS AFTER COMPLETION OF STUDY TREATMENT Active, not recruiting NCT01720524 Phase 3 placebo;iv sildenafil
14 Multicenter, Double-blind, Placebo-controlled, Randomized, Prospective Study of Bosentan as Adjunctive Therapy to Inhaled Nitric Oxide in the Management of Persistent Pulmonary Hypertension of the Newborn (PPHN) Terminated NCT01389856 Phase 3 Bosentan;Matching placebo
15 The Randomized Inhaled Nitric Oxide Study (NINOS) in Full-Term and Nearly Full-Term Infants With Hypoxic Respiratory Failure Terminated NCT00005776 Phase 3 Inhaled nitric oxide;Placebo
16 Early Inhaled Nitric Oxide Therapy in Term and Near Term Infants With Respiratory Failure Terminated NCT00005773 Phase 3 Inhaled Nitric Oxide;Standard iNO therapy
17 Intramuscular 17Alpha-hydroxyprogestrone, Progesterone Suppositories and Dydrogesterone Tablets in Preventing Preterm Labor Unknown status NCT03537287 Phase 2 17 alpha hydroxyprogestrone caproate;Vaginal progesterone;Oral dydrogesterone
18 Nebulized Magnesium Sulfate for Treatment of Persistent Pulmonary Hypertension of The Newborn Completed NCT04328636 Phase 1, Phase 2 Nebulized Magnesium Sulfate;Intravenous Magnesium Sulfate
19 Impact of the NO-donor Pentaerythrithyltetrantrate on Perinatal Outcome in High-risk Pregnancies: a Prospective Randomized Pilot Study Completed NCT01355822 Phase 1, Phase 2 PETN;Placebo control
20 Efficacy and Safety of Paracetamol in Comparison to Ibuprofen for Patent Ductus Arteriosus Treatment in Preterm Infants: A Randomized, Open Label, Comparator-controlled, Prospective Study Completed NCT02422966 Phase 2 Paracetamol;Ibuprofen
21 Intravenous Remodulin (Treprostinil) as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Randomized, Placebo-Controlled, Safety and Efficacy Study Recruiting NCT02261883 Phase 2 IV Remodulin;Placebo
22 Milrinone in Congenital Diaphragmatic Hernia Recruiting NCT02951130 Phase 2 Milrinone;Placebo (5% Dextrose)
23 Effect of a Parenteral Emulsion Parenteral With Long-chain Polyunsaturated Fatty Acids Omega 3 on Clinical Outcomes, Inflammatory and Oxidative Stress Markers in Neonates With Persistent Pulmonary Hypertension Active, not recruiting NCT04031508 Phase 2
24 A Single Arm Single Centre Study To Investigate Safety And Efficacy Of Sildenafil In Near Term And Term Newborns With Persistent Pulmonary Hypertension Of The Newborn (PPHN) Terminated NCT01069861 Phase 2 sildanefil
25 An Open Label Single Arm, Single Centre Study to Investigate the Safety and Efficacy of IV Sildenafil in Neonates With Persistent Pulmonary Hypertension of the Newborn (PPHN) Withdrawn NCT01360671 Phase 2 Sildenafil
26 A Randomized, Double Blind, Placebo-controlled Pilot Study of the Safety and Effective Dosing of Inhaled Iloprost in Pediatric Patients With Pulmonary Hypertension Treated With Inhaled Nitric Oxide Withdrawn NCT00981591 Phase 1, Phase 2 Iloprost;Placebo
27 Randomized Clinical Trial of Inhaled PGE1 (IPGE1) in Neonatal Hypoxemic Respiratory Failure. A Protocol for the NICHD Neonatal Research Network Withdrawn NCT00598429 Phase 2 Inhaled Prostaglandin E1
28 Ibuprofen vs. Indomethacin as Second Course of Therapy for Resistant PDA in Low Birth Weight Neonates Withdrawn NCT01070745 Phase 2 Indomethacin;Ibuprofen
29 Pharmacokinetics of Sildenafil in Premature Infants Completed NCT01670136 Phase 1 1 dose of sildenafil
30 Effect and Placental Transfer of Dexmedetomidine During Caesarean Section Under Epidural Anaesthesia Completed NCT02715154 Phase 1 Dexmedetomidine;Placebo
31 A Dose - Dependent Study of Dexmedetomidine in Suppressing Cardiovascular and Hormonal Responses for Cesarean Delivery Completed NCT01005433 Phase 1 Dexmedetomidine;Placebo
32 Examination of Perfusion Index in Term and Preterm Newborns Through Plethismography Unknown status NCT02380040
33 Compare of Continued Nitro Oxide Inhalation and Nitro Oxide Inhalation Continued With Oral Sildenafil on Treatment of Neonatal Persistent Pulmonary Hypertension Unknown status NCT01373749 NO inhalation;NO inhalation continued with sildenafil
34 ECMO in Newborn Infants: Circulatory Changes in Relation to Venovenous and Venoarterial Bypass. Implications for Peripheral Organ Circulation Unknown status NCT00622492
35 Efficacy of Intravenous Immunoglobulin in Management of RH and ABO Incompatibility Disease of Newborn and Its Effect in Decrease Duration of Hospital Stay and Need for Exchange Transfusion Unknown status NCT03130517 Early Phase 1 intravenous immunoglobulin
36 Mortality and Morbidity of Infants Born With Gestational Age Less Than 28 Weeks Unknown status NCT01150396
37 Examination of Diaplacental Transfer of IgG-antibodies Against Human Cytomegalovirus (HCMV) and Varicella-Zoster-Virus (VZV) at Premature and Mature Newborns Unknown status NCT02689700
38 P-wave Duration and Dispersion in Intrahepatic Cholestasis of Pregnancy Unknown status NCT01906827
39 Ephedrine, Phenylephrine and Metaraminol Effects on Maternal Cardiac Output, Uterine Blood Flow and Fetal Circulation in Patients With Preeclampsia Under Spinal Anesthesia for Cesarean Unknown status NCT02245191 Ephedrine;Phenylephrine;Metaraminol
40 Relation of Implantation Site to Placental Site in Presence or Absence of Cesarean Section Scar With Doppler Assessment of Retro Chorionic Blood Flow Unknown status NCT03208842
41 Machine Learning From Fetal Flow Waveforms to Predict Adverse Perinatal Outcomes Unknown status NCT03398551
42 A Comparison of Fetal Hemodynamic Measurements Between Pregnant Women Taking Anti-Hypertensive Medication and Controls Unknown status NCT00759278
43 Epidemiology of Persistent Pulmonary Hypertension of the Newborn - SCOR in Lung Biology and Diseases in Infants and Children Completed NCT00005323
44 Persistent Pulmonary Hypertension of the Newborn (PPHN) Observational Study Completed NCT01203423
45 Risk Factors for Pulmonary Hypertension of the Newborn Completed NCT00005497
46 NO Need to Ventilate: A Trial of Non-invasive iNO in Persistent Pulmonary Hypertension of the Newborn Completed NCT00139217 iNO
47 A Feasibility Study to Consider the Relationship Between Markers of Red Cell Damage, Inflammation and the Recovery Process of Newborns Requiring Extracorporeal Membrane Oxygenation (ECMO) for Persistent Pulmonary Hypertension of the Newborn (PPHN): Mi-ECMO Completed NCT02940327
48 Antibody Secreting Cell (ASC) and Immunoactive Protein Profiles in Neonates on Extracorporeal Membrane Oxygenation (ECMO) Completed NCT00371241
49 Assessment of Cerebral Circulation and Perfusion in Adults After Neonatal Carotid Occlusion Completed NCT00646672
50 Administration of Inhaled Nitric Oxide (iNO) as an Adjunct to Neonatal Resuscitation Protocol: A Pilot Trial Completed NCT01220687 iNO

Search NIH Clinical Center for Persistent Fetal Circulation Syndrome

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Tolazoline
Tolazoline Hydrochloride

Cochrane evidence based reviews: persistent fetal circulation syndrome

Genetic Tests for Persistent Fetal Circulation Syndrome

Genetic tests related to Persistent Fetal Circulation Syndrome:

# Genetic test Affiliating Genes
1 Persistent Fetal Circulation Syndrome 29 FOXF1

Anatomical Context for Persistent Fetal Circulation Syndrome

MalaCards organs/tissues related to Persistent Fetal Circulation Syndrome:

40
Lung, Heart, Brain, Uterus, Placenta, Testes, Fetal Lung

Publications for Persistent Fetal Circulation Syndrome

Articles related to Persistent Fetal Circulation Syndrome:

(show top 50) (show all 198)
# Title Authors PMID Year
1
Two autopsy cases of siblings with alveolar capillary dysplasia: clinical and post-mortem issues. 61
31512071 2020
2
Are Cardiac Anomalies and Persistent Fetal Circulation a Risk Factor for Cardiovascular Events During Minimally Invasive Surgery in Neonates? 61
30994398 2019
3
Impact of circle of Willis anatomy in traumatic blunt cerebrovascular injury-related stroke. 61
29766090 2017
4
Neurologic and neuroimaging manifestations of Cantú syndrome: A case series. 61
27316244 2016
5
Ruptured Tricuspid Valve Papillary Muscle in a Neonate with Intractable Persistent Fetal Circulation. 61
26240590 2015
6
[Correction of Acidosis in Neonatal Intensive-care Medicine: A National Survey]. 61
25811742 2015
7
Wide clinical variability in conditions with coarse facial features and hypertrichosis caused by mutations in ABCC9. 61
23307537 2013
8
Neonates presenting with temperature symptoms: role in the diagnosis of early onset sepsis. 61
22299645 2012
9
[Persistent fetal vasculature syndrome--clinical image and diagnostic difficulties]. 61
22384655 2011
10
Implication of pulse oxymetry screening for detection of congenital heart defects. 61
20458668 2010
11
Changes in pulmonary arterial pressure in term-infants with hypoxic-ischemic encephalopathy. 61
19419507 2009
12
Tracheal occlusion for fetal congenital diaphragmatic hernia: the US experience. 61
19559324 2009
13
Fibromuscular dysplasia with carotid artery dissection presenting as an isolated hemianopsia. 61
17689408 2007
14
Pulmonary arterial hypertension. 61
16581695 2006
15
Pulmonary stabilisation followed by delayed surgery results in favourable outcome in congenital cystic lung lesions with pulmonary hypertension. 61
16125963 2005
16
Increased incidence of cardiac anomalies in pregnancies complicated by gastroschisis. 61
16157146 2005
17
Preoperative ECMO in transposition of the great arteries with persistent pulmonary hypertension. 61
15919337 2005
18
Factors affecting short-term mortality in very low birth weight infants in Japan. 61
15673972 2005
19
Neonatal post-intubation subglottic stenosis. 61
15535351 2004
20
Prostaglandin E1 treatment in patent ductus arteriosus dependent congenital heart defects. 61
15346826 2004
21
[Echocardiography is a useful tool in neonatal intensive care settings: a Lebanese experience]. 61
15623132 2003
22
Extracorporeal life support for severe adult respiratory failure. 61
17021448 2003
23
Acute respiratory disorders in the newborn at the Mount Hope Women's Hospital, Trinidad. 61
12806750 2003
24
Development of disposable self-regulating blood pumps and automatically-controlled portable extracorporeal membrane oxygenation systems for neonatal extracorporeal membrane oxygenation. 61
12580779 2003
25
Persistent fetal circulation. 61
20084150 2001
26
Oxidative stress and increased type-IV collagenase levels in bronchoalveolar lavage fluid from newborn babies. 61
11420415 2001
27
Persistent pulmonary hypertension of the newborn: experience in a single institution. 61
11355072 2001
28
The effects of dopamine and epinephrine on hemodynamics and oxygen metabolism in hypoxic anesthetized piglets. 61
11353933 2001
29
Beat-to-beat changes in stroke volume precede the general circulatory effects of mechanical ventilation: a case report. 61
11178225 2001
30
Acute respiratory failure associated with intrathoracic masses in neonates. 61
10591558 1999
31
Cytokines, pulmonary surfactant and consequences of intrauterine infection. 61
10393386 1999
32
Active-phase labor arrest: oxytocin augmentation for at least 4 hours. 61
10074971 1999
33
Management of prenatally diagnosed congenital cystic adenomatoid malformation of the lung. 61
10207706 1999
34
Current obstetrical practice and umbilical cord prolapse. 61
10774764 1999
35
Treatment of inflammatory rheumatic disorders in pregnancy: what are the safest treatment options? 61
9825952 1998
36
Economic evaluation and randomised controlled trial of extracorporeal membrane oxygenation: UK collaborative trial. The Extracorporeal Membrane Oxygenation Economics Working Group. 61
9756807 1998
37
Hypoxic pulmonary vasoconstriction is impaired in rats with nitrofen-induced congenital diaphragmatic hernia. 61
9766353 1998
38
Pulmonary arterioles from rats with congenital diaphragmatic hernias are hypoplastic but not hyperresponsive. 61
9766355 1998
39
A case of multiple aneurysms of the vein of Galen with heart failure due to persistent fetal circulation. 61
28921251 1998
40
Fibrous fusion between the liver and the lung: an unusual complication of right congenital diaphragmatic hernia. 61
9607495 1998
41
Alpha-smooth muscle actin distribution in the pulmonary vasculature comparing hypoplastic and normal fetal lungs. 61
9566278 1998
42
Echocardiographic prediction of neonatal ECMO outcome. 61
9175523 1997
43
[Pulmonary causes of hypoxia in premature infants and its therapeutic possibilities]. 61
9244887 1997
44
[Premature labor, determination of fetal lung maturity and medicamentous induction of lung maturation]. 61
9410531 1997
45
Systemic, pulmonary and mesenteric perfusion and oxygenation effects of dopamine and epinephrine. 61
9001285 1997
46
The effects of venous occlusion on cerebral blood flow characteristics during ECMO. 61
8863247 1996
47
UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation. UK Collaborative ECMO Trail Group. 61
8676720 1996
48
Nitric oxide and lung surfactant. 61
8870120 1996
49
Is there a correlation between aortic Doppler velocimetric findings in diabetic pregnant women and fetal outcome? 61
8738987 1996
50
Surgical repair of transposition of the great arteries in neonates with persistent pulmonary hypertension. 61
8619696 1996

Variations for Persistent Fetal Circulation Syndrome

ClinVar genetic disease variations for Persistent Fetal Circulation Syndrome:

6 (show top 50) (show all 79) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 FOXF1 NM_001451.3(FOXF1):c.683_690GCGGCGGC[1] (p.Ala231fs)short repeat Pathogenic 692054 16:86544858-86544865 16:86511252-86511259
2 FOXF1 NM_001451.3(FOXF1):c.89C>A (p.Ser30Ter)SNV Pathogenic 800366 16:86544264-86544264 16:86510658-86510658
3 FOXF1 NM_001451.3(FOXF1):c.145C>G (p.Pro49Ala)SNV Pathogenic 800377 16:86544320-86544320 16:86510714-86510714
4 FOXF1 NM_001451.3(FOXF1):c.145C>T (p.Pro49Ser)SNV Pathogenic 800365 16:86544320-86544320 16:86510714-86510714
5 FOXF1 NM_001451.3(FOXF1):c.191C>A (p.Ser64Ter)SNV Pathogenic 800369 16:86544366-86544366 16:86510760-86510760
6 FOXF1 NM_001451.3(FOXF1):c.221T>A (p.Ile74Asn)SNV Pathogenic 800371 16:86544396-86544396 16:86510790-86510790
7 FOXF1 NM_001451.3(FOXF1):c.294C>A (p.His98Gln)SNV Pathogenic 800373 16:86544469-86544469 16:86510863-86510863
8 FOXF1 NM_001451.3(FOXF1):c.316T>C (p.Phe106Leu)SNV Pathogenic 800375 16:86544491-86544491 16:86510885-86510885
9 FOXF1 NM_001451.3(FOXF1):c.539C>A (p.Ser180Ter)SNV Pathogenic 800372 16:86544714-86544714 16:86511108-86511108
10 FOXF1 NM_001451.3(FOXF1):c.849_850del (p.Ile285fs)deletion Pathogenic 800376 16:86545024-86545025 16:86511418-86511419
11 FOXF1 NM_001451.3(FOXF1):c.862C>T (p.Gln288Ter)SNV Pathogenic 800374 16:86545037-86545037 16:86511431-86511431
12 FOXF1 NM_001451.3(FOXF1):c.872_879del (p.Leu290_Ser291insTer)deletion Pathogenic 800367 16:86545040-86545047 16:86511434-86511441
13 FOXF1 NM_001451.3(FOXF1):c.899_903dup (p.Gly302fs)duplication Pathogenic 800368 16:86545071-86545072 16:86511465-86511466
14 FOXF1 NM_001451.3(FOXF1):c.1031_1032del (p.Phe344fs)deletion Pathogenic 800364 16:86546581-86546582 16:86512975-86512976
15 FOXF1 NM_001451.3(FOXF1):c.1139G>C (p.Ter380Ser)SNV Pathogenic 800370 16:86546690-86546690 16:86513084-86513084
16 FOXF1 NM_001451.3(FOXF1):c.1057_1078dup (p.Gly360fs)duplication Pathogenic 916530 16:86546605-86546606 16:86512999-86513000
17 FOXF1 NM_001451.3(FOXF1):c.253T>C (p.Phe85Leu)SNV Pathogenic 916531 16:86544428-86544428 16:86510822-86510822
18 FOXF1 NM_001451.3(FOXF1):c.225C>A (p.Tyr75Ter)SNV Pathogenic 8462 rs121909336 16:86544400-86544400 16:86510794-86510794
19 FOXF1 NM_001451.3(FOXF1):c.1138T>C (p.Ter380Arg)SNV Pathogenic 8463 rs121909337 16:86546689-86546689 16:86513083-86513083
20 FOXF1 FOXF1, 1-BP DUP, 775Tduplication Pathogenic 8464
21 FOXF1 FOXF1, 2-BP DEL, 956TTdeletion Pathogenic 8465
22 46;XY;t(9;16)(p24;q22)dnTranslocation Pathogenic 267798
23 subset of 22 genes: FOXC2 , FOXF1 GRCh37/hg19 16q24.1-24.2(chr16:84872102-87678641)copy number loss Pathogenic 813309 16:84872102-87678641
24 FOXF1 NM_001451.3(FOXF1):c.1140A>C (p.Ter380Cys)SNV Likely pathogenic 560714 rs1567511932 16:86546691-86546691 16:86513085-86513085
25 FOXF1 NM_001451.3(FOXF1):c.413G>C (p.Arg138Pro)SNV Likely pathogenic 816907 16:86544588-86544588 16:86510982-86510982
26 FOXF1 NM_001451.3(FOXF1):c.*1176deldeletion Conflicting interpretations of pathogenicity 320830 rs397854726 16:86547856-86547856 16:86514250-86514250
27 FOXF1 NM_001451.3(FOXF1):c.*471_*472dupduplication Uncertain significance 320810 rs56130003 16:86547153-86547154 16:86513547-86513548
28 FOXF1 NM_001451.3(FOXF1):c.*310_*311insTinsertion Uncertain significance 320804 rs67178865 16:86547001-86547002 16:86513395-86513396
29 FOXF1 NM_001451.3(FOXF1):c.-4C>TSNV Uncertain significance 320785 rs752749806 16:86544172-86544172 16:86510566-86510566
30 FOXF1 NM_001451.3(FOXF1):c.*123dupduplication Uncertain significance 320800 rs886052379 16:86546810-86546811 16:86513204-86513205
31 FOXF1 NM_001451.3(FOXF1):c.1081G>A (p.Gly361Arg)SNV Uncertain significance 320794 rs886052377 16:86546632-86546632 16:86513026-86513026
32 FOXF1 NM_001451.3(FOXF1):c.*1137A>GSNV Uncertain significance 320828 rs886052383 16:86547828-86547828 16:86514222-86514222
33 FOXF1 NM_001451.3(FOXF1):c.60_62del (p.Gly23del)deletion Uncertain significance 320787 rs757668134 16:86544233-86544235 16:86510627-86510629
34 FOXF1 NM_001451.3(FOXF1):c.*1298dupduplication Uncertain significance 320835 rs886052386 16:86547982-86547983 16:86514376-86514377
35 FOXF1 NM_001451.3(FOXF1):c.*1182T>GSNV Uncertain significance 320832 rs886052385 16:86547873-86547873 16:86514267-86514267
36 FOXF1 NM_001451.3(FOXF1):c.*1095C>ASNV Uncertain significance 320826 rs377544296 16:86547786-86547786 16:86514180-86514180
37 FOXF1 NM_001451.3(FOXF1):c.*909G>ASNV Uncertain significance 320825 rs561764653 16:86547600-86547600 16:86513994-86513994
38 FOXF1 NM_001451.3(FOXF1):c.*682G>ASNV Uncertain significance 320819 rs886052382 16:86547373-86547373 16:86513767-86513767
39 FOXF1 NM_001451.3(FOXF1):c.*646G>TSNV Uncertain significance 320817 rs781403145 16:86547337-86547337 16:86513731-86513731
40 FOXF1 NM_001451.3(FOXF1):c.636G>C (p.Ser212=)SNV Uncertain significance 689448 rs776649998 16:86544811-86544811 16:86511205-86511205
41 FOXF1 NM_001451.3(FOXF1):c.*309_*310insTinsertion Uncertain significance 320803 rs11392376 16:86547000-86547001 16:86513394-86513395
42 FOXF1 NM_001451.3(FOXF1):c.*260T>CSNV Uncertain significance 320802 rs886052380 16:86546951-86546951 16:86513345-86513345
43 FOXF1 NM_001451.3(FOXF1):c.*71C>ASNV Uncertain significance 320798 rs886052378 16:86546762-86546762 16:86513156-86513156
44 FOXF1 NM_001451.3(FOXF1):c.*16C>TSNV Uncertain significance 320795 rs754401391 16:86546707-86546707 16:86513101-86513101
45 FOXF1 NM_001451.3(FOXF1):c.980-10C>TSNV Likely benign 320793 rs368414616 16:86546521-86546521 16:86512915-86512915
46 FOXF1 NM_001451.3(FOXF1):c.*370G>ASNV Likely benign 320807 rs527370416 16:86547061-86547061 16:86513455-86513455
47 FOXF1 NM_001451.3(FOXF1):c.*591G>TSNV Likely benign 320814 rs75593355 16:86547282-86547282 16:86513676-86513676
48 FOXF1 NM_001451.3(FOXF1):c.*632G>ASNV Likely benign 320816 rs186301477 16:86547323-86547323 16:86513717-86513717
49 FOXF1 NM_001451.3(FOXF1):c.*467_*468insAinsertion Likely benign 320811 rs201645265 16:86547158-86547159 16:86513552-86513553
50 FOXF1 NM_001451.3(FOXF1):c.*631C>TSNV Likely benign 320815 rs147615917 16:86547322-86547322 16:86513716-86513716

Expression for Persistent Fetal Circulation Syndrome

Search GEO for disease gene expression data for Persistent Fetal Circulation Syndrome.

Pathways for Persistent Fetal Circulation Syndrome

Pathways related to Persistent Fetal Circulation Syndrome according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.33 NOS3 LEP INS IGF1
2
Show member pathways
12.33 PGF NOS3 INS IGF2 IGF1 CSH2
3
Show member pathways
12.25 NOS3 LEP INS CSH2 CSH1
4
Show member pathways
12.07 POMC LEP INS IGF1
5 11.86 INS IGF1 FOXF1 ALB
6 11.71 LEP INS IGF1
7
Show member pathways
11.7 POMC NOS3 IGF1 EDN1 CSH2 CSH1
8 11.69 POMC NOS3 CRH
9 11.66 NOS3 INS IGF1 EDN1
10 11.4 INS IGF2 IGF1
11 11.3 INS FOXF1 ALB
12 11.2 INS IGF1 HSD11B2
13
Show member pathways
11.02 POMC LEP EDN1
14
Show member pathways
10.85 IGF2 IGF1 EDN1
15 10.65 PDE5A NOS3
16 10.63 POMC LEP INS
17 10.37 POMC CRH

GO Terms for Persistent Fetal Circulation Syndrome

Cellular components related to Persistent Fetal Circulation Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 POMC PGF OXT LEP INS IGF2
2 extracellular space GO:0005615 9.47 POMC PGF OXT LEP INS IGF2
3 platelet alpha granule lumen GO:0031093 9.33 IGF2 IGF1 ALB

Biological processes related to Persistent Fetal Circulation Syndrome according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.13 POMC PGF PDE5A OXT LEP INS
2 positive regulation of cell migration GO:0030335 9.94 INS IGF1 FOXF1 EDN1
3 cell-cell signaling GO:0007267 9.94 POMC PGF INS EDN1
4 in utero embryonic development GO:0001701 9.93 NOS3 IGF2 FOXF1 EDN1
5 cellular protein metabolic process GO:0044267 9.92 INS IGF2 IGF1 ALB
6 positive regulation of protein phosphorylation GO:0001934 9.88 PGF LEP IGF2 CRH
7 response to hypoxia GO:0001666 9.86 PGF LEP HSD11B2 EDN1
8 lung development GO:0030324 9.84 NOS3 FOXF1 CRH
9 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.83 LEP INS IGF1
10 positive regulation of MAPK cascade GO:0043410 9.81 LEP INS IGF2 IGF1
11 response to nutrient levels GO:0031667 9.79 LEP CSH2 CSH1
12 glucose metabolic process GO:0006006 9.77 LEP INS IGF2
13 response to activity GO:0014823 9.72 OXT LEP EDN1
14 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.71 IGF2 IGF1 CSH2 CSH1
15 positive regulation of cell proliferation GO:0008284 9.7 PGF LEP INS IGF2 IGF1 EDN1
16 positive regulation of JAK-STAT cascade GO:0046427 9.67 LEP CSH2 CSH1
17 positive regulation of cell growth involved in cardiac muscle cell development GO:0061051 9.66 IGF1 EDN1
18 positive regulation of renal sodium excretion GO:0035815 9.66 OXT EDN1
19 growth hormone receptor signaling pathway GO:0060396 9.65 CSH2 CSH1
20 positive regulation of growth GO:0045927 9.65 CSH2 CSH1
21 positive regulation of cardiac muscle hypertrophy GO:0010613 9.65 PDE5A IGF1 EDN1
22 glucocorticoid biosynthetic process GO:0006704 9.63 HSD11B2 CRH
23 positive regulation of insulin receptor signaling pathway GO:0046628 9.63 LEP INS IGF2
24 negative regulation of smooth muscle cell apoptotic process GO:0034392 9.62 IGF1 EDN1
25 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.62 LEP IGF1 CSH2 CSH1
26 ovulation from ovarian follicle GO:0001542 9.61 NOS3 LEP
27 positive regulation of prostaglandin secretion GO:0032308 9.59 OXT EDN1
28 bone mineralization involved in bone maturation GO:0035630 9.58 LEP IGF1
29 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.57 NOS3 EDN1
30 regulation of blood pressure GO:0008217 9.56 POMC NOS3 LEP EDN1
31 negative regulation of glucagon secretion GO:0070093 9.54 LEP CRH
32 positive regulation of glycogen biosynthetic process GO:0045725 9.54 INS IGF2 IGF1
33 response to ether GO:0045472 9.52 OXT CRH
34 female pregnancy GO:0007565 9.35 PGF OXT LEP HSD11B2 CRH
35 positive regulation of mitotic nuclear division GO:0045840 8.92 INS IGF2 IGF1 EDN1

Molecular functions related to Persistent Fetal Circulation Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 insulin receptor binding GO:0005158 9.43 INS IGF2 IGF1
2 growth factor activity GO:0008083 9.35 PGF IGF2 IGF1 CSH2 CSH1
3 insulin-like growth factor receptor binding GO:0005159 9.33 INS IGF2 IGF1
4 growth hormone receptor binding GO:0005131 9.32 CSH2 CSH1
5 hormone activity GO:0005179 9.32 POMC OXT LEP INS IGF2 IGF1

Sources for Persistent Fetal Circulation Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....